Triple therapy aims to turn inoperable bowel cancer into surgical candidates
Disease control
Not yet recruiting
This study tests whether combining chemotherapy (FOLFOX), a targeted drug (fruquintinib), and an immunotherapy (serplulimab) can shrink advanced colorectal cancer enough to allow surgery. About 42 adults with a specific genetic type (pMMR/MSS) who have not had prior treatment wil…
Phase: PHASE4 • Sponsor: Ye Xu • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC